Sputum and serum calprotectin are useful biomarkers during CF exacerbation

Journal of Cystic Fibrosis

Volumn 9, Issue 3, 2010, Pages 193-198

  Gray, R D ^a   Imrie, M ^a   Boyd, A C ^a   Porteous, D ^a   Innes, J A ^a   Greening, A P ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; INTERLEUKIN 8; MYELOPEROXIDASE; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOCYTE COUNT; LUNG DISEASE; MALE; NEUTROPHIL; PREDICTION; PROTEIN BLOOD LEVEL; SPUTUM LEVEL; BLOOD; CHEMISTRY; DISEASE COURSE; MIDDLE AGED; SPUTUM; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; SPUTUM; YOUNG ADULT;

EID: 77953350894     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.01.005     Document Type: Article

References (42)

1. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J January 1 2004, 23(1):146-158.
2. Goss C.H., Burns J.L. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax Apr 2007, 62(4):360-367.
3. Hiatt P.W., Grace S.C., Kozinetz C.A., Raboudi S.H., Treece D.G., Taber L.H., et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics Mar 1999, 103(3):619-626.
4. Aaron S.D., Ramotar K., Ferris W., Vandemheen K., Saginur R., Tullis E., et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med Apr 1 2004, 169(7):811-815.
5. Smith A.L., Redding G., Doershuk C., Goldmann D., Gore E., Hilman B., et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr Apr 1988, 112(4):547-554.
6. Ordonez C.L., Henig N.R., Mayer-Hamblett N., Accurso F.J., Burns J.L., Chmiel J.F., et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med Dec 15 2003, 168(12):1471-1475.
7. Colombo C., Costantini D., Rocchi A., Cariani L., Garlaschi M.L., Tirelli S., et al. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol Jul 2005, 40(1):15-21.
8. Marshall B.C. Pulmonary exacerbations in cystic fibrosis: it's time to be explicit!. Am J Respir Crit Care Med Apr 1 2004, 169(7):781-782.
9. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med Sep 8 1994, 331(10):637-642.
10. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med Jan 7 1999, 340(1):23-30.
11. Rabin H.R., Butler S.M., Wohl M.E., Geller D.E., Colin A.A., Schidlow D.V., et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol May 2004, 37(5):400-406.
12. Sagel S.D., Kapsner R., Osberg I., Sontag M.K., Accurso F.J. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med Oct 15 2001, 164(8 Pt 1):1425-1431.
13. Sagel S.D., Sontag M.K., Wagener J.S., Kapsner R.K., Osberg I., Accurso F.J. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr Dec 2002, 141(6):811-817.
14. Salva P.S., Doyle N.A., Graham L., Eigen H., Doerschuk C.M. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol Jan 1996, 21(1):11-19.
15. Henig N.R., Tonelli M.R., Pier M.V., Burns J.L., Aitken M.L. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax Apr 2001, 56(4):306-311.
16. McGarvey L.P., Dunbar K., Martin S.L., Brown V., Macmahon J., Ennis M., et al. Cytokine concentrations and neutrophil elastase activity in bronchoalveolar lavage and induced sputum from patients with cystic fibrosis, mild asthma and healthy volunteers. J Cyst Fibros Dec 2002, 1(4):269-275.
17. Sloane A.J., Lindner R.A., Prasad S.S., Sebastian L.T., Pedersen S.K., Robinson M., et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med Dec 1 2005, 172(11):1416-1426.
18. Regelmann W.E., Siefferman C.M., Herron J.M., Elliott G.R., Clawson C.C., Gray B.H. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr Pulmonol Jan 1995, 19(1):1-9.
19. Meyer K.C. Neutrophils, myeloperoxidase, and bronchiectasis in cystic fibrosis: green is not good. J Lab Clin Med Sep 2004, 144(3):124-126.
20. Ordonez C.L., Kartashov A.I., Wohl M.E. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis. J Pediatr Nov 2004, 145(5):689-692.
21. Sagel S.D., Kapsner R.K., Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol Mar 2005, 39(3):224-232.
22. Downey D.G., Martin S.L., Dempster M., Moore J.E., Keogan M.T., Starcher B., et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol Mar 2007, 42(3):216-220.
23. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., et al. Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis. Am J Respir Crit Care Med Apr 15 2007, 175(8):822-828.
24. Macgregor G., Gray R.D., Hilliard T.N., Imrie M., Boyd A.C., Alton E.W., et al. Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid. J Cyst Fibros Sep 2008, 7(5):352-358.
25. Gray R.D., MacGregor G., Noble D., Imrie M., Dewar M., Boyd A.C., et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med Sep 1 2008, 178(5):444-452.
26. Wilson G.B., Fudenberg H.H., Jahn T.L. Studies on cystic fibrosis using isoelectric focusing. I. An assay for detection of cystic fibrosis homozygotes and heterozygote carriers from serum. Pediatr Res August 1975, 9(8):635-640.
27. Dorin J.R., Novak M., Hill R.E., Brock D.J., Secher D.S., Van Heyningen V. A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene. Nature 1987, 326(6113):614-617.
28. Vogl T., Tenbrock K., Ludwig S., Leukert N., Ehrhardt C., Van Zoelen M.A., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med Sep 2007, 13(9):1042-1049.
29. Raquil M.A., Anceriz N., Rouleau P., Tessier P.A. Blockade of antimicrobial proteins S100A8 and S100A9 inhibits phagocyte migration to the alveoli in streptococcal pneumonia. J Immunol Mar 1 2008, 180(5):3366-3374.
30. Downey D.G., Brockbank S., Martin S.L., Ennis M., Elborn J.S. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol Aug 1 2007, 42(8):729-735.
31. Reid D.W., Misso N., Aggarwal S., Thompson P.J., Walters E.H. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology Jan 2007, 12(1):63-69.
32. Rowe S.M., Jackson P.L., Liu G., Hardison M., Livraghi A., Solomon G.M., et al. Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease. Am J Respir Crit Care Med October 15 2008, 178(8):822-831.
33. McColley S.A., Stellmach V., Boas S.R., Jain M., Crawford S.E. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med Jun 2000, 161(6):1877-1880.
34. Pizzichini E., Pizzichini M.M., Efthimiadis A., Hargreave F.E., Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J Jun 1996, 9(6):1174-1180.
35. Boussac M., Garin J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis Feb 2000, 21(3):665-672.
36. Voganatsi A., Panyutich A., Miyasaki K.T., Murthy R.K. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol Jul 2001, 70(1):130-134.
37. Fagerhol M.K. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet Nov 25 2000, 356(9244):1783-1784.
38. Costa F., Mumolo M.G., Ceccarelli L., Bellini M., Romano M.R., Sterpi C., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut Mar 2005, 54(3):364-368.
39. Cohen J.C., Larson J.E. Pathophysiologic consequences following inhibition of a CFTR-dependent developmental cascade in the lung. BMC Dev Biol 2005, 5:2.
40. Husson M.O., Wizla-Derambure N., Turck D., Gosset P., Wallaert B. Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis. J Antimicrob Chemother Jul 2005, 56(1):247-249.
41. Ordonez C.L., Stulbarg M., Grundland H., Liu J.T., Boushey H.A. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001 Jul, 32(1):29-37.
42. Watt A.P., Courtney J., Moore J., Ennis M., Elborn J.S. Neutrophil cell death, activation and bacterial infection in cystic fibrosis. Thorax Aug 2005, 60(8):659-664.